Xolair 75 MG/0.5 ML syringe 0.5ML
Ended Awarded
- Contract number
- SPE2DB25FDRCK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,642
Award facts
- Contract value 100% obligated
- $4,642.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $4,642.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 24, 2025, for the supply of Xolair 75 mg/0.5 ml syringes. The contract, which carries an ultimate completion date of October 16, 2025, does not utilize a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge location. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency, valued at $499,999,999 and valid through November 2026, which enables the issuance of firm fixed-price orders for a comprehensive range of pharmaceutical products supporting military health facility operations.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with a robust portfolio of delivery orders covering branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities. The company's specialized distribution capabilities—ranging from contraceptive devices to oncology treatments and injectable medications—position it to fulfill the Defense Logistics Agency's extensive pharmaceutical sourcing requirements. This particular delivery order for Xolair, a monoclonal antibody treatment used in immunology, represents one of numerous pharmaceutical product acquisitions the agency executes through its established contract vehicle with the vendor.
Quick answers
Who was awarded contract SPE2DB25FDRCK?
SPE2DB25FDRCK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 24, 2025.
How much is contract SPE2DB25FDRCK worth?
The government has obligated $4,642 on SPE2DB25FDRCK.
Is contract SPE2DB25FDRCK an order under another contract?
Yes. SPE2DB25FDRCK is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB25FDRCK competed?
The extent of competition for SPE2DB25FDRCK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award